T-knife is set out to revolutionize the TCR landscape with its unique and proprietary transgenic HuTCR mouse platform to produce fully human TCRs. These TCRs mimic the properties of virus-specific TCRs avoiding immunological tolerance to self tumor antigens in humans.
T-knife’s TCRs do not require additional modification but are naturally selected in vivo for an optimal affinity/specificity combination. The Company´s lead TCR has entered clinical development in an academic investigator-initiated study in patients with multiple myeloma.
T-knife was founded in 2018 by Thomas Blankenstein, Elisa Kieback and Holger Specht as spin-off from Max-Delbruck Center for Molecular Medicine with support of Charité University Hospital in Berlin/Germany and the mission to bring novel, sophisticated T cell receptor-based therapeutics to market. Based on the unparalleled T cell immunology expertise of its founders and the unique and proprietary HuTCR platform, the Company develops fully human TCRs which are expected to set new technology standards achieving superior safety and efficacy.
The Company has demonstrated preclinical proof-of-concept and its lead compound has entered clinical development. In addition, T-knife has validated the platform for over 90 undisclosed cancer targets, with several follow-on drug candidates being already in preclinical development.